Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

UCLA pediatric investigators earn top accolades at TTCF Faculty Presentation Awards

UCLA pediatric investigators earn top accolades at TTCF Faculty Presentation Awards

YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis

YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Mimicry allows bacteria to evade host's defense responses

Mimicry allows bacteria to evade host's defense responses

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Geophagy protects stomach against toxins, parasites and pathogens

Geophagy protects stomach against toxins, parasites and pathogens

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

Shield raises EUR8.2M through Series A financing

Shield raises EUR8.2M through Series A financing

HbA1c glucose monitoring test not effective for diagnosing diabetes patients with kidney failure

HbA1c glucose monitoring test not effective for diagnosing diabetes patients with kidney failure

YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.